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The impact of increased NF-κB-inducing kinase (NIK), a key component of the NF-κB activation pathways, on diabetes-induced
renal inﬂammation remains unknown. We overexpressed NIK wild type (NIKwt) or kinase-dead dominant negative mutants
(NIKdn) in HK-2 cells and demonstrated that RelB and p52, but not RelA, abundance and DNA binding increased in nuclei of
NIKwt but not NIKdn overexpressed cells, and this corresponded with increases in multiple proinﬂammatory cytokines. Since
TRAF3 negatively regulates NIK expression, we silenced TRAF3 by >50%; this increased nuclear levels of p52 and RelB, and
transcript levels of proinﬂammatory cytokines and transcription factors. In HK-2 cells and mouse primary proximal tubule
epithelial cells treated with methylglyoxal-modiﬁed albumin, multiple proinﬂammatory cytokines and NIK were increased in
association with increased nuclear RelB and p52. These observations indicate that NIK regulates proinﬂammatory responses
of renal proximal tubular epithelial cells via mechanisms involving TRAF3 and suggest a role for NF-κB noncanonical pathway
activation in modulating diabetes-induced inﬂammation in renal tubular epithelium.
1.Introduction
The concept that diabetes is a chronic inﬂammatory dis-
ease is supported by signiﬁcant clinical and experimen-
tal data indicating that chronic, low-grade inﬂammation
is a common denominator linking obesity, insulin resis-
tance, atherosclerosis, dyslipidemia, and excessive glucose
metabolism in diabetes [1–4]. Numerous diabetic stimuli,
including elevated glucose, glycation products, and reactive
oxygen species, have been shown to activate nuclear factor-
κB( N F - κB) in relevant renal cells [5–7], contributing to
the proinﬂammatory diabetic milieu. The NF-κBf a m i l y
of transcription factors is controlled by distinct canonical
and noncanonical activation pathways. The former plays
an important role in the host innate immune response
by inducing the expression of numerous proinﬂammatory
cytokines, chemokines, adhesion molecules, growth factors,
and inducible enzymes [8–11]. The latter plays an important
role in the adaptive immune response, including secondary
lymphoid organogenesis and lymphocyte maturation [12–
14]. This pathway is mediated by NF-κB-inducing kinase
(NIK)·IKKα complexes that process p100 into p52 that
translocates into the nucleus as a complex with RelB.
We and others have reported the increased expression
of numerous NF-κB-regulated proinﬂammatory/proangi-
ogenic signaling cytokines, chemokines, and growth factors
in the renal cortex of db/db mice, indicating a dysreg-
ulated and prolonged activation of the NF-κB canonical
pathway [15]. Additionally, we have observed several fold
increases in NIK expression in the renal cortex of db/db
mice that was localized to renal proximal tubular epithelial
cells. The pathophysiological signiﬁcance of this ﬁnding
remains unknown, although NIK has been shown to be
a potent proinﬂammatory kinase in a variety of cells and
tissues.2 Experimental Diabetes Research
Table 1: List of antibodies used against the protein targets.
Target Species Dilution Company MW (kDa)
NIK Rabbit 1:1,000 Cell signaling 4994 >100
TRAF3 Rabbit 1:500 Santa Cruz sc949 65
p52/p100 Mouse 1:1,000 Upstate 05-361 52/100
RelB Rabbit 1:500 Santa Cruz sc226 68
RelA Rabbit 1:2,000 Rockland100-4165 65
β-tubulin Rabbit 1:5,000 Santa Cruz sc9104 55
Lamin B Goat 1:5,000 Santa Cruz sc6216 67
β-actin Mouse 1:20,000 Sigma A1978 42
β-actin Rabbit 1:20,000 Sigma A2103 42
Table 2: Secondary antibodies.
Name of the secondary antibody Company
IRDye 800 Aﬃnity Puriﬁed Antimouse
IgG (goat) Rockland, 610-132-121
IRDye 800 Aﬃnity Puriﬁed Antigoat IgG
(donkey) Rockland, 605-731-125
IRDye 800 Aﬃnity Puriﬁed Antirabbit
IgG (goat) Rockland, 611-132-122
Alexa Fluor 680 goat antimouse IgG Invitrogen A21057
Alexa Fluor 680 donkey antigoat IgG Invitrogen A21084
Alexa Fluor 680 goat antirabbit IgG Invitrogen A21109
All secondary antibodies were used at a 1:5,000 dilution.
Based on our animal studies, we have suggested that
diabetes activates both canonical and noncanonical NF-κB
pathways, leading to renal inﬂammation, and the diabetes-
induced activation of the NF-κB noncanonical pathway via
theupstreamNIKplaysacausalroleinprolongingtheinnate
immune response activated by the canonical pathway. In this
study,wehaveusedhumanHK-2cellsandprimaryproximal
epithelium (pPEC) harvested from mouse renal cortex to
probe the role of noncanonical NF-κB pathway activation in
response to manipulation of NIK and TRAF3 levels as well as
methylglyoxal-modiﬁed human serum albumin (MG-HSA),
a stimulus that mimics the in vivo diabetic milieu.
2.MaterialsandMethods
2.1. Materials and Antibodies. All chemicals used were from
Sigma. A list of primary and secondary antibodies used can
be found in Tables 1 and 2.
2.2. Cell Culture. Human kidney cortex proximal tubu-
lar cells, HK-2 (ATCC), were grown and maintained in
the recommended medium, Dulbecco’s modiﬁed Eagle’s
medium/Ham’s F12 (50/50) supplemented with 10% fetal
bovine serum, L-glutamine, insulin, transferrin, sodium
selenite, EGF (2.5ng/mL), and pituitary extract (1.5μg/mL)
in a humidiﬁed atmosphere of 5% CO2.
2.3.PrimaryCultureofMouseProximalTubuleEpithelialCells
(pPEC). Renal cortical tubular epithelial cells were isolated
and cultured using published techniques with modiﬁcations
[16]. Brieﬂy, 12–16-week C57BL/6 male mice were used
to prepare primary renal proximal tubule cell cultures.
Kidneys were sliced into coronal sections and cortical tissue
separated from the medullary portion of each kidney under
magniﬁcation with a dissecting microscope, minced, then
washed 3x in ice cold DMEM-F12 media containing 0.1%
BSA,followedbyenzymaticdigestionusing1%Worthington
collagenase Type II and 0.25% soybean trypsin inhibitor.
Cell suspensions were passed through 200 mesh followed
by 325 mesh ﬁlters, then resuspended in 45% Percoll and
centrifuged at ∼27,000× gf o r1 5 m i na t4 ◦C. Proximal
tubule cells were sedimented to a layer immediately above
theerythrocytepellet.Thesecellswereremoved,centrifuged,
washed to remove the remaining Percoll, then resuspended
in Dulbecco’s modiﬁed Eagle’s medium/F-12 containing
50units/mL of penicillin, 50μg/mL streptomycin, 10ng/mL
e p i d e r m a lg r o w t hf a c t o r ,0 . 5 μM hydrocortisone, 0.87μM
bovine insulin, 50μM prostaglandin E1,5 0 n Ms o d i u m
selenite, 50μg/mL human transferrin, and 5pM 3,3 ,5-
triiodo-L-thyronine. Cells were plated on Matrigel-coated
coverslips, or plastic cell culture dishes coated with Matrigel,
andmaintained inanincubatorat37◦Cin5%CO 2.C ultur es
were left undisturbed for 48hr, after which culture media
was replaced every 2 days until cells achieved conﬂuence.
For all experiments, cells were used within three passages as
described [16].
2.4. NIK Transfection. HK-2 cells were transfected with the
eukaryotic expression vectors pCDNA-MycNIK or pCDNA-
MycNIK dominant negative, encoding NIK Thr559Phe site
mutant as described previously [17], or empty vector
plasmid DNA (pCDNA) using either lipofectamine and Plus
Reagent (Invitrogen, Carlsbad, CA) or by electroporation
using Cell Line Nucleofector Kit V (Amaxa Biosystems)
according to the manufacturers’ instructions. Cells were
cultured for variable times as indicated below, and either
whole cell lysates or cytosolic and nuclear extracts were
prepared.
2.5. Gene Silence by siRNA. TRAF3 siRNA and nontargeting
control siRNA (Dharmacon Smart Pools, Lafayette, CO)
(SMART pools) were transfected into HK-2 cells by TransIT-
siQUEST Transfection Reagent (Mirus Corp., Madison, WI)
at 50nmol/L or 100nmol/L ﬁnal concentration according to
the manufacturer’s instructions. Up to 72hr posttransfec-
tion, cells were used for measuring TRAF3 knockdown and
cytokine production.
2.6. Preparation of Methylglyoxal-Modiﬁed Serum Albumin.
Human serum albumin (HSA) minimally modiﬁed by
methylglyoxal (MG) was prepared as described (3) by incu-
bation of the protein (100μM) in sodium phosphate buﬀer
(100mM, pH 7.4 and 37◦C) with 500μMm e t h y l g l y o x a l
for 24 hours. MG-modiﬁed protein was dialyzed against
ammonium bicarbonate buﬀer (30mM, pH 7.9 and 4◦C)
for 24hrs, followed by a PBS dialysis buﬀer for another
24hrs;sterilizedbyﬁltration(0.22μm),aliquoted,andstoredExperimental Diabetes Research 3
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Figure 1: MG-HSA increased NF-κB-mediated cytokine production in HK-2 and primary proximal tubular epithelial cells: (a) Cytokines
were measured on aliquots of tissue culture supernatant using customized human multiplex kits, using the Bio-Plex system according to
the manufacturer’s instructions. Experiments were performed twice in triplicate, and data normalized to control (HK-2 cells exposed to
unmodiﬁed HSA) values. Data represent mean ± SD of two independent experiments and compared using 1-way ANOVA (signiﬁcance
values are shown within each panel). (b) Renal primary tubular epithelial cells were treated with MG-HSA (5μM) for various times, and
expression levels of IL-6, IL-8, MCP-1, and NIK were measured in a single experiment performed in triplicate (error bars represent SD of
intra-assay variability) by using Q-RT-PCR. Data were normalized to GAPDH and expressed as fold change as compared to the untreated
cells (Control).4 Experimental Diabetes Research
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Figure 2: NIK overexpression in HK-2 cells increases noncanonical NF-κB pathway activation: HK-2 cells were transfected with the eukaryotic
expression vectors pCDNA-MycNIK (NIKwt) or pCDNA-MycNIK dominant negative (NIKdn), encoding NIK Thr559P h es i t em u t a n to r
empty vector (ev) plasmid DNA (pCDNA). (a) Representative Western blot showing expression of NIKwt and NIKdn transfected at the
same plasmid concentration; (b) Western blot showing nuclear RelB on the left and quantiﬁcation of 4 separate experiments on the right;
(c) Representative Western blot showing cytosolic and nuclear p100 and p52 on the left and quantiﬁcation of nuclear p52 from 5 separate
experiments on the right. P100 is predominantly cytosolic and despite the increase in nuclear p52, it did not change in abundance. (d)
Representative Western blot showing cytosolic and nuclear RelA on the left and quantiﬁcation of nuclear RelA from 4 separate experiments
on the right. Bar graph data are presented as mean ± SE; Student’s t-test versus empty vector control (ev): ∗P<0.05.
−80◦C until used. The extent of methylglyoxal modiﬁcation
was determined using a Hitachi L-8800 amino acid analyzer.
Unmodiﬁed protein was processed similarly for control
experiments.
2.7. Preparation of Cell Lysates. For whole cell lysates, culture
media was removed, plates rinsed with ice cold PBS, and
cells scraped using ice cold PBS (1mL/100mm dish) and
transferred to eppendorf tubes, then spun at 2000rpm for
2minat4 ◦C. The supernatant was removed and 100–500 μL
1x RIPA buﬀer-containing protease (Sigma, catalog #P8340)
and phosphatase (1mM orthovanadate and 30mM sodium
ﬂuoride) inhibitors was added to cell pellet for 30min on
ice with periodic vortexing, followed by centrifugation for
15min at 4◦C at 13,200rpm. The supernatant was stored as
w h o l ec e l ll y s a t ea t−80◦C.
For cytosolic and nuclear extracts, the cell pellet was
obtained from culture plates as above, and 100–300μL
solution A (50mM HEPES, pH 7.9, 10mMKCl, 1mM
EDTA, 1mM EGTA, protease inhibitor cocktail (Sigma),
phosphatase inhibitors [1mM orthovanadate and 30mM
sodium ﬂuoride], 1mM DTT, and 0.5mM phenylmethyl-
sulphonylﬂuoride [PMSF]) was added with gentle mixing
by pipeting, then incubated on ice for 10min. 10% NP-
40 was added for a ﬁnal concentration of 0.5%, and theExperimental Diabetes Research 5
cells immediately spun for 7min at 1,000g at 4◦C. The
supernatant was used as cytosolic extract. The pellet was
gently resuspended in 1:1 (v:v) solution B (50mmol/L
HEPES, pH 7.9, 10mM KCl, 1mM EDTA, 1mM EGTA,
34% sucrose, protease and phosphatase inhibitors, 1mM
DTT, and 0.5mM PMSF), then spun at 7400g for 5min
at 4◦C. The supernatant was removed and discarded, and
the pellet was resuspended in 10μLs o l u t i o nAf o l l o w e d
by 40μL of solution C (50mM HEPES, pH 7.9, 500mM
KCl, 1mM EDTA, 1mM EGTA, 10% glycerol, protease and
phosphataseinhibitors,1mMDTT,and0.5mMPMSF)with
gentle vortexing. The suspension was allowed to sit on ice
for 30min, vortexing every 5min, then spun at 16, 100g for
20min at 4◦C. The supernatant was used as nuclear extract.
Protein concentrations of nuclear and cytosolic extracts were
determined using the Bio-Rad (Hercules, CA) protein assay
with bovine albumin standards, and both samples were
assayed for cytosolic (β-tubulin) and nuclear (lamin B)
proteins.
2.8. Western Immunoblot Analysis. Whole cell, nuclear and
cytoplasmiclysateswereelectrophoresedon7.5or10%SDS-
polyacrylamide gels and analyzed by immunoblotting after
transfer to nitrocellulose membranes (Bio-Rad Laboratories,
Hercules, CA), using primary antibodies (Table 1) according
to each manufacturer’s instructions, followed by species-
speciﬁc secondary antibodies tagged with a ﬂuorescent dye
(IR Dye 800; Rockland) at a 1:5,000 dilution (Table 2).
Densitometric quantitation of each protein was performed
using the LI-COR Bioscience Odyssey Imaging System with
infrared ﬂuorescence detection or with an ECL system onto
ﬁlm. β-actin was measured on every blot (using an IR Dye
700 with the LI-COR system) for evaluation of protein
loading.
2.9. DNA Binding Assay. TransAM NF-κB Family Transcrip-
tion Factor Assay Kit (Cat no. 43296, ActiveMotif) was used
for the DNA-binding assay according to the manufacturer’s
instructions. Brieﬂy, oligonucleotide containing an NF-κB
consensus binding site was immobilized on a 96-well plate,
and activated NF-κB subunits contained in nuclear extract
were added and speciﬁcally bound to this oligonucleotide.
Antibodies directed against speciﬁc NF-κB subunits (RelA,
RelB, p50, p52) complexed with the oligonucleotide were
added, followed by rinsing and addition of a secondary
antibody conjugated to horseradish peroxidase for spec-
trophotometric quantiﬁcation.
2.10. Quantitative Real-Time PCR (qRT-PCR). Total RNA
was extracted using acid guanidinium-phenol extraction
(TRIreagent;Sigma,T9494)accordingtothemanufacturer’s
instructions. Two to ﬁve micrograms of RNA were reverse
transcribed using SuperScript III (Invitrogen Corp.) in a 20-
μL reaction mixture. One microliter of cDNA product was
diluted 1:2, and 2μL were ampliﬁed in a 20-μLr e a c t i o n
mixture containing 12.5μL of SYBR green supermix (Bio-
Rad) and 0.2μM each of forward and reverse gene-speciﬁc
0
1
2
3
4
RelB p52 RelA
F
o
l
d
c
h
a
n
g
e
v
e
r
s
u
s
c
o
n
t
r
o
l
(a)
0
0.5
1
1.5
2
2.5
3
3.5
∗
∗
∗ ∗
IL-6 IL-8 TNF RANTES
F
o
l
d
c
h
a
n
g
e
v
e
r
s
u
s
c
o
n
t
r
o
l
MCP-1
(b)
Figure 3: DNA-binding assay and cytokine measurements: (a)
TransAM NF-κB Family Transcription Factor Assay was used to
measure RelA, RelB, and p52 DNA binding following NIKwt
and NIKdn overexpression in HK-2 cells. For each Rel protein,
ev (left), NIKwt (middle), and NIKdn (right) are shown. Data
represent two separate experiments. One-way ANOVA: P<0.02.
(b) Cytokine measurements determined using tissue culture media
obtained from the same experiments. Data represent two separate
experiments. Two-way ANOVA: P<0.008. Student’s t-test versus
empty vector control: ∗P<0.05.
primers (SuperArray Bioscience Corp), aliquoted into 96-
well, 0.2-mm thin-wall PCR plates. Plates were denatured
for 90sec at 95◦C, then subjected to 40 cycles of 15sec at
94◦C, 60sec at 60◦C, and 1min at 72◦Ci na ni C y c l e r( B i o -
Rad).Foreachexperimentalsample,triplicatereactionswere
conducted in 96-well plates. The ΔΔCt method was used to
analyze the experimental data with GAPDH or β-actin used
as internal standard.
2.11. Cytokine Measurements. Multiple cytokines and
chemokines were measured on aliquots of tissue culture
supernatant or cytosolic extracts using customized human
or mouse cytokine/chemokine kits (Millipore) with the
Bio-Plex system, used with the Luminex xMAP technology
according to the manufacturer’s instructions (Bio-Rad
Laboratories, Hercules, CA). Eight-point standard curves
were performed for each cytokine using the same Luminex
bead technology.6 Experimental Diabetes Research
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Figure 4: TRAF3 siRNA knockdown: TRAF3 was knocked down using speciﬁc siRNA by TransIT-siQUEST Transfection Reagent in HK-2
cells. (a) Representative Western blot demonstrating eﬀects of 100 nM TRAF3 siRNA after 48 and 72 hours with β-actin as a loading control
is shown on the left and quantiﬁcation of the pooled 48 and 72 hour data is shown on the right. All subsequent experiments used 100nM
siRNA. (b) Representative Western blot showing nuclear RelB on the left and quantiﬁcation of 2 separate experiments on the right; (c)
Representative Western blot showing nuclear p52 on the left and quantiﬁcation of 3 separate experiments on the right; (d) Representative
WesternblotshowingnuclearRelAontheleftandquantiﬁcationofoneexperimentontheright.Student’st-testversusemptyvectorcontrol:
∗P<0.05.Experimental Diabetes Research 7
2.12. Statistical Analysis. All results are expressed as means
± SD or SEM as indicated. For assessment of cytokine
data, one-way and two-way ANOVA tests were performed
to evaluate overall group diﬀerences. This was followed by
appropriateposthocteststodeterminepairwisesigniﬁcance.
For all other two sample comparisons, a Student’s t-test
was performed after checking for variance distribution via
Levene’stest.Inallcases,P<0.05wasconsideredsigniﬁcant.
3. Results
3.1. MG-HSA Increases NF-κB-Mediated Cytokine Production
in HK-2 Cells and Mouse pPEC in Tissue Culture. HK-2
cells were grown to 80% conﬂuence then treated with 5μM
MG-HSA for up to 24 hours in tissue culture. Figure 1(a)
demonstrates time-dependent, increased production of NF-
κB-related cytokines, including IL-6, IL-8, and MCP-1,
measured in aliquots of the tissue culture media. Similar
results were obtained using RT-PCR assay for cytokines in
MG-HSA-treatedprimaryproximaltubulesofmousekidney
cortex exposed to the same concentration of MG-HSA,
including increased production of NIK, measured over a 24-
hour time period (Figure 1(b)).
3.2. NIK Overexpression in HK-2 Cells Increases Noncanonical
NF-κB Pathway Activation. Overexpression of NIKwt and
NIKdn plasmids in HK-2 cells is shown in Figure 2(a).T h e
increased NIKwt protein was associated with 2-fold increases
in nuclear RelB (Figure 2(b)) and 4-fold increases in nuclear
p52 (Figure 2(c)). P100 was predominantly expressed in the
cytoplasm, and despite the signiﬁcant increase in p100 pro-
cessing to p52, it did not change in abundance. Insigniﬁcant
increases in nuclear Rel A were observed with no change in
cytosolic expression levels (Figure 2(d)). Overexpression of
NIKdn did not increase RelA, RelB, or p52 nuclear protein.
The increased nuclear protein was associated with >2-fold
increases in RelB and p52 DNA binding but no increase
in RelA DNA binding (Figure 3(a)). Most cytokine levels
in NIKwt-overexpressed cells were increased 2-fold, while
NIKdn expression had no eﬀect (Figure 3(b)). In contrast to
the eﬀects of MG-HSA (shown in Figure 1), overexpression
of NIKwt did not increase MCP-1 production.
3.3. TRAF3 siRNA Knockdown. Low basal levels of NIK are
maintained in cells by regulating its turnover by TRAFs. In
nonstimulated cells, TRAF-3 recruits NIK to the complex
containing TRAF2 and cIAP1/2. In this complex, NIK
undergoes ubiquitination by cIAP1/2 resulting in rapid
proteosomal degradation. However, in the presence of
noncanonical stimuli, cIAP1/2 ubiquitinates and promotes
degradation of TRAF3, thereby releasing NIK from negative
regulation by TRAF and leading to its stabilization and
accumulation in the cells. To understand the physiological
relevance of TRAF3-mediated regulation of NIK steady-state
levels, TRAF3 was knocked down using speciﬁc siRNA by
TransIT-siQUEST Transfection Reagent as per the manufac-
turer protocol. TRAF3 knockdown was eﬀective at 100nM
plasmid concentration after 48- and 72-hours shown by
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Figure 5: TRAF3 silencing increases proinﬂammatory proteins:
TRAF3 was knocked down using speciﬁc siRNA in HK-2 cells, and
cytokines (IL-8 and MCP-1) and retinoid x receptor alpha (RXRA)
were measured by RT-PCR in a single experiment performed in
triplicate (error bars represent SD of intra-assay variability).
Western blot in Figure 4(a). An average of the 48 and 72
hour western blots obtained from two separate experiments
is tabulated on the right in Figure 4(a).
TRAF3 silencing increased nuclear content of RelB
(Figure 4(b))andp52(Figure 4(c))withoutaﬀectingnuclear
RelA (Figure 4(d)). Cytokine levels in HK-2 measured by
RT-PCR, including IL-8 and MCP-1, as well as the retinoid
acid receptor alpha (RXRA) were increased 2- to 2.5-fold by
TRAF3 silencing (Figure 5).
4. Discussion
NF-κB is a family of highly inducible cytoplasmic DNA
binding proteins that includes the transactivating subunits,
RelA, RelB, c-Rel, and the posttranslationally processed
DNA-binding subunits, NF-κB 1 (p50) and NF-κB2 (p52)
[18]. NF-κB dimers remain sequestered in the cytoplasm
by interacting with a group of inhibitory ankyrin repeat-
containing proteins, collectively referred to as IκBs (IκBα,
IκBβ,I κBγ, p100, and p105) [19]. Recently, it has been
appreciated that NF-κB activation can be controlled by at
least two separate and independent pathways: the “canonical
pathway” mediated by the IκB kinase (IKK, a complex of two
catalytic subunits, IKKα and IKKβ and the regulatory sub-
unit, IKKγ)[ 20] and the “noncanonical pathway” mediated
by a complex of IKKα and NIK. Stimuli activating NF-κB
via the canonical pathway activate IKK kinase, resulting in
IκBα phosphorylation at speciﬁc N-terminal serine residues
targeting them for proteasomal degradation [21]. This
process releases sequestered RelA·p50 to enter the nucleus.
To date, the noncanonical pathway has been shown to
play a role in the adaptive immune response, including
secondary lymphoid organogenesis, the induction of genes
involved in this process, and lymphocyte maturation [12–
14]. Recently, it has been observed that the noncanonical8 Experimental Diabetes Research
pathway can be activated in response to speciﬁc stimuli,
including lymphotoxin β [LTβ][ 22, 23], CD40 ligand
[24], DNA virus infection [25], and B-cell activating factor
[BAFF] [12, 26, 27]. Interestingly, neither IKKγ nor IKKβ,
key regulators of the canonical pathway, are required for
activation of the noncanonical pathway [12, 23]. Rather,
a kinase complex consisting of NIK and IKKα activates
posttranslational processing of p100 into the 52kDa-active
DNA-binding isoform. Newly formed p52 dimerizes with
cytoplasmic RelB and translocates into the nucleus. In this
p a t h w a y ,N I Ks e rv e st oa c t i v a t eI K K α and provides a docking
site to recruit both p100 and IKKα [23]. NIK therefore is an
essential component of the noncanonical NF-κBa c t i v a t i o n
pathway.
NIKisa110kDaser-thrkinase ﬁrstidentiﬁedasaTRAF-
binding protein in yeast two hybrid screening. Because of
its ability to activate both IKKα and IKKβ, NIK has been
extensively studied as an upstream kinase regulating NF-
κB activation pathways [22, 23, 28–30]. The observation
that an NIK·IKKα complex is responsible for proteolytic
processing of p100 to generate p52 has generated signiﬁcant
interest in understanding the molecular role of NIK as a
regulator of NF-κB activation. However, the physiological
and pathophysiological role of NIK remains mostly unex-
plored, and very few in vivo studies have explored the impact
of increased NIK activation. It has been reported in pig
models of ischemia-reperfusion injury and in delayed graft
function in patients receiving kidney transplants [31]. In the
latter, activation of NIK occurred within proximal tubular
epithelial cells, in a pattern strikingly similar to the diabetes-
induced changes we have reported. NIK activity also can be
induced by thrombin in cultured proximal tubular epithelial
cells [31].
We have postulated that diabetes activates both canonical
and noncanonical NF-κB pathways, leading to renal inﬂam-
mation. Since NF-κB activation is well known to be rapidly
arrested,animportant,unansweredquestioniswhythisdoes
not occur in diabetic tissues, where canonical pathway acti-
vation of the innate immune response persists chronically,
contributing signiﬁcantly to the inﬂammatory/angiogenic
phenotype reported in diabetic tissues. Since this is very
diﬃcult to test in vivo, and while NIK is constitutively
produced, but is kept at very low intracellular levels by
TRAF3, we utilized overexpression systems in tissue culture
to probe the impact of elevated NIK levels on canonical
versus noncanonical inﬂammation. We have shown that a
relevant diabetic stimulus, methylglyoxal-modiﬁed human
serum albumin, can activate NF-κB to increase cytokine
production, and that this is associated with increases in
NIK levels. Furthermore, increasing endogenous NIK levels
via transfection of full-length NIK suﬃcient to overwhelm
endogenous TRAF3-mediated regulatory mechanisms, or
silencing TRAF3, both lead to increased cytokine production
similar to that observed with relevant diabetic stimuli.
Importantly,thiswasassociatedwithincreasesintheamount
as well as increases in DNA binding of nuclear NF-κB
proteins related to the noncanonical activation pathway
(RelB and p52) without measurable changes in nuclear RelA.
These changes were not linked to the plasmid transfection,
since overexpression of NIK protein lacking kinase activity
did not result in similar RelB and p52 nuclear changes.
5. Conclusions
Elevating cellular levels of NIK by overexpression or by
silencing TRAF3, an endogenous posttranslational regu-
latory mechanism for NIK, resulted in increased nuclear
translocation of RelB and p52, and increased DNA binding
of these Rel proteins relative to the canonical RelA protein.
This resulted in increased cytokine production similar to
that observed with methylglyoxal-modiﬁed albumin. These
observations indicate that NIK regulates proinﬂammatory
responses of renal proximal tubular epithelial cells via
mechanisms involving TRAF3 and suggest a role for NF-
κB noncanonical pathway activation in modulating diabetes-
induced inﬂammation in renal tubular epithelium.
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